RxDoctor Payments Data

William Palmer, MD

Family Medicine · Perry, IANPI 1417363573

Payments from drug & device makers

$2,626in general payments, 2019–2025

Across 114 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$856
  • Johnson & Johnson$756
  • AstraZeneca$323
  • Novo Nordisk$262
  • Amgen$142
  • E.r. Squibb & Sons, L.L.C.$140
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$2,53897%
  • Education$883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,626 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$2,152
Medicare patients
11
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide158$184,073
EliquisApixaban102$90,994
JardianceEmpagliflozin48$55,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$44,298
MounjaroTirzepatide26$26,269
Synjardy XrEmpagliflozin/Metformin Hcl19$23,139
SynjardyEmpagliflozin/Metformin Hcl15$20,538
MyrbetriqMirabegron24$17,532
TrulicityDulaglutide15$14,340
LinzessLinaclotide23$11,661
RybelsusSemaglutide12$11,401
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,153
Repatha SureclickEvolocumab11$9,127
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$8,838
Humalog Kwikpen U-100Insulin Lispro17$6,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$262$195,474170 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat$19$107,94699 claims
PfizerEliquis$12$90,994102 claims
Lilly USA, LLCMounjaro, Trulicity$45$40,60941 claims
AbbVieLinzess$856$11,66123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Perry

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →